Please login to the form below

Not currently logged in
Email:
Password:

Ipsen reveals new strategy

Ipsen has published a comprehensive review of its future corporate strategy

Ipsen has unveiled its latest business strategy, which will see it invest in research and grow its operations in the US.

Marc de Garidel, chairman and chief executive of Ipsen, said: "Our strategy is threefold: first, increase focus through the creation of a new franchise-based organisation and increase R&D specialisation on two innovative and differentiated technological platforms, peptides and toxins. Second, within areas of focus, increase significant investments to enhance our research and commercial competitiveness.

"Last, leverage our international footprint, particularly in the USA and in the pharmerging markets, to gain global market share. We thus aspire at more than doubling our 2010 revenues and tripling our 2010 EBIT by 2020."

The company revealed that it expects to record one-off pre-tax costs of up to €100m in 2011 and 2012 related to the transfer of the US commercial operations to the East Coast, the closure of the Barcelona R&D site and other one-off costs related to the implementation of the strategy and of the new organisation.

9th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics